Given the strong demand expected for Eli Lilly's (NYSE:LLY) weight loss treatment Zepbound (tirzepatide) in the UK, the ...
One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...
Eli Lilly (NYSE:LLY) has been making headlines recently with its weight-loss drug Zepbound (tirzepatide). Eli Lilly ...
The trial enrolled 751 adults with obesity or overweight conditions and at least one weight-related medical problem ...
Drugmaker Eli Lilly and Co. will invest $3 billion and add 750 employees in Kenosha County as the company expands a plant it ...
Eli Lilly (LLY) plans to boost production of its popular diabetes and weight-loss medications with a $3B expansion of its ...